GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a tripeptide naturally present in human blood plasma, saliva, and urine. Discovered in 1973 by Dr. Loren Pickart, this peptide complex has an exceptional affinity for copper (II) ions, forming a stable chelate that constitutes one of the main physiological copper transporters in the body.

The plasma concentration of GHK-Cu decreases significantly with age: from approximately 200 ng/mL at age 20, it drops to approximately 80 ng/mL around age 60. This decline correlates with the age-related slowdown of tissue regenerative capacities, which has directed research toward anti-aging and regenerative applications of this peptide.

GHK-Cu is one of the few bioactive peptides that has been the subject of clinical studies in the dermatological field. Its well-characterized safety profile and natural presence in the body make it a particularly interesting candidate for cosmetic formulations and applications in cutaneous regenerative medicine. GHK-Cu is a key component of blends such as Klow Peptide and Glow Peptide. For a detailed article on its anti-aging applications, see GHK-Cu: the anti-aging peptide.

The mechanism of action of GHK-Cu relies on its ability to extensively modulate gene expression. Transcriptomic studies have revealed that this peptide influences the expression of more than 4,000 human genes, approximately 6% of the genome. Among the activated pathways are those involved in tissue repair, antioxidant defense (via superoxide dismutase and glutathione peroxidase), and synthesis of extracellular matrix components.

At the skin level, GHK-Cu stimulates the production of type I, III, and V collagen by dermal fibroblasts, as well as the synthesis of proteoglycans (decorin) and glycosaminoglycans. It also activates the production of matrix metalloproteinases (MMP-2) involved in tissue remodeling, while inhibiting excessive pro-inflammatory MMPs. This dual role promotes orderly matrix remodeling.

The copper ion plays an essential catalytic role in these processes. It serves as a cofactor for lysyl oxidase, a key enzyme in collagen and elastin cross-linking, and for mitochondrial cytochrome c oxidase, thereby supporting cellular energy metabolism. GHK-Cu also exerts anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines (IL-6, TNF-alpha) and by modulating the activity of the nuclear factor NF-kB.

GHK-Cu benefits from a solid body of research spanning more than five decades, since its discovery in 1973. Studies have progressed from initial in vitro observations to controlled clinical trials, particularly in the dermatological field. Several randomized double-blind clinical trials have been published, evaluating the efficacy of GHK-Cu in topical creams for skin rejuvenation.

Transcriptomic studies conducted by the Pickart and Campbell team constituted a major breakthrough by revealing the extent of GHK-Cu's genomic action. This work, using DNA microarray technology (Connectivity Map), identified the signaling pathways modulated by the peptide, opening new therapeutic perspectives in the fields of pulmonary fibrosis, neurodegenerative diseases, and oncology.

The cosmetic applications of GHK-Cu are the best clinically validated, with several commercialized products containing this peptide. Current research focuses on regenerative medicine applications, including chronic wound healing, bone regeneration, and neuroprotection. Preclinical studies are also exploring its potential in the treatment of COPD and idiopathic pulmonary fibrosis.

GHK-Cu has a well-established safety profile, benefiting from a long history of use in cosmetic dermatology. Published clinical studies report excellent skin tolerance, with no significant irritation or notable allergic reactions at concentrations used in topical formulations (generally 0.01% to 1%). Repeated skin sensitization tests have not revealed any allergenic potential.

As a natural component of human plasma, GHK-Cu has an intrinsic advantage in terms of biocompatibility. In vitro cytotoxicity studies confirm the absence of cellular toxicity at physiological and supraphysiological concentrations. However, high concentrations of free copper could theoretically induce oxidative stress; the chelated GHK-Cu form minimizes this risk by ensuring controlled release of the copper ion.

Side effects reported in the literature are rare and generally mild, limited to transient redness or a slight tingling sensation upon topical application. No adverse systemic effects have been documented during topical use. For non-topical routes of administration, safety data remain more limited and require further investigation.